Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast06: T-DXd vs Chemotherapy in HR+ HER2-Low/Ultra-Low Breast Cancer
NCT04494425Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by AstraZeneca. Started Jul 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04494425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494425.